GSK2606414

GSK2606414
Identifiers
	IUPAC name 1-[5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)indolin-1-yl]-2-(3-trifluoromethylphenyl)ethanone;
CAS Number	1337531-36-8 ;
PubChem CID	53469448;
ChemSpider	28643060;
UNII	DPP2K6EFW8;
PDB ligand	0WH (PDBe, RCSB PDB);
Chemical and physical data
Formula	C24H20F3N5O
Molar mass	451.453 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C2=NC=NC(N)=C2C(C3=CC(CCN4C(CC5=CC(C(F)(F)F)=CC=C5)=O)=C4C=C3)=C1;
	InChI InChI=1S/C24H20F3N5O/c1-31-12-18(21-22(28)29-13-30-23(21)31)15-5-6-19-16(11-15)7-8-32(19)20(33)10-14-3-2-4-17(9-14)24(25,26)27/h2-6,9,11-13H,7-8,10H2,1H3,(H2,28,29,30); Key:SIXVRXARNAVBTC-UHFFFAOYSA-N;

GSK2606414 is a drug which is the first selective inhibitor discovered for the enzyme protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), which is involved in various processes relating to cancer and neurodegenerative disorders. GSK2606414 was found to be a potent and selective inhibitor of PERK, with good oral bioavailability and blood-brain barrier penetration.^[1] PERK mediates the unfolded protein response pathway which is involved in the initiation of protein synthesis, and this pathway has been implicated in the neurotoxicity of various diseases including prion and Alzheimer's diseases. Treatment with GSK2606414 was found to be neuroprotective in mice against damage caused by prions, and prevented the development of cognitive deficits and other clinical manifestations of prion disease. Extension of lifespan in treated mice was, however, not recorded. However, side effects such as weight loss and elevated blood glucose levels were also observed, likely due to unwanted inhibition of PERK in the pancreas gland, where it is involved in regulating insulin production.^[2]

References

^ Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, et al. (August 2012). "Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK)". Journal of Medicinal Chemistry. 55 (16): 7193–207. doi:10.1021/jm300713s. PMID 22827572.
^ Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM, et al. (October 2013). "Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice". Science Translational Medicine. 5 (206): 206ra138. doi:10.1126/scitranslmed.3006767. PMID 24107777. S2CID 25570626.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, et al. (August 2012). "Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK)". Journal of Medicinal Chemistry. 55 (16): 7193–207. doi:10.1021/jm300713s. PMID 22827572.

[2] Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM, et al. (October 2013). "Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice". Science Translational Medicine. 5 (206): 206ra138. doi:10.1126/scitranslmed.3006767. PMID 24107777. S2CID 25570626.

[1]

[2]